< Back to front page Text size – +

Today's Globe: stem cell research rules, healthcare lobbyists, Gaucher drugs

E-mail | Print | Comments () Posted by Elizabeth Cooney July 7, 2009 06:54 AM

Facebook
E-mail

The federal government issued final rules yesterday that expand taxpayer-funded research using embryonic stem cells, easing scientists’ fears that some of the oldest batches might not qualify and promising a master list of all that do.

The nation’s largest insurers, hospitals, and medical groups have hired more than 350 former government staff members and retired members of Congress in hopes of influencing their old bosses and colleagues, according to an analysis of lobbying disclosures and other records.

The Food and Drug Administration is moving to speed up access to experimental drugs for Gaucher disease to help offset likely shortages of Cerezyme, the top-selling drug made by Genzyme Corp.

Facebook
E-mail

« Back to front page

About white coat notes

White Coat Notes covers the latest from the health care industry, hospitals, doctors offices, labs, insurers, and the corridors of government. Chelsea Conaboy previously covered health care for The Philadelphia Inquirer. Write her at cconaboy@boston.com. Follow her on Twitter: @cconaboy.

Daily Dose | More Health&Wellness

health answers

Long-term health consequences to being born prematurely? It's estimated that each year nearly 500,000 babies in the United States are born prematurely, or before 37 weeks of pregnancy. Submit question | More answers